Innovent Biologics Advances IBI354 HER2 ADC Into Pivotal First-Line Breast Cancer Trial, Backed by Phase 1/2 Efficacy and a Low Toxicity Signal

China-based Innovent Biologics (HKEX: 01801) announced the dosing of the first participant in HeriCare-Breast01, a pivotal Phase III study evaluating IBI354, a HER2-targeted antibody–drug conjugate carrying a camptothecin-derivative payload, as first-line treatment for patients with unresectable locally advanced or metastatic HER2-positive breast cancer. The Innovent HER2 antibody drug conjugate enters a crowded and fast-moving competitive field in which Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan has already posted Phase III data that could reset the standard of care, making the differentiation IBI354 claims on safety — particularly a low rate of interstitial lung disease — a central question for the program's viability.

Trial specifics: HeriCare-Breast01 design and supporting IBI354 Phase 3 clinical trial data

HeriCare-Breast01 (NCT07377643) is a multicenter, randomized, open-label, active-controlled study comparing IBI354, with or without pertuzumab, against the current standard of care — paclitaxel plus trastuzumab and pertuzumab (THP). The primary endpoint is progression-free survival. The trial is designed to test whether a next-generation HER2 ADC first-line breast cancer regimen can outperform the taxane-antibody backbone established by the CLEOPATRA trial more than a decade ago. The press release did not disclose the planned enrollment size, the number of study arms, or the geographic scope of the trial, though the principal investigator is based at the Cancer Hospital of the Chinese Academy of Medical Sciences.

No Phase III efficacy data are available, as the study has only just begun dosing. Innovent instead cited results from a multicenter Phase 1/2 study in patients with advanced solid tumors, presented at ASCO 2025. Among 88 patients with HER2-positive breast cancer who had received a median of four prior lines of therapy, the confirmed objective response rate across dose levels of 6–15 mg/kg was 59.1%, with a disease control rate of 90.9%. In the 29-patient subgroup treated at 9 mg/kg every three weeks — the dose that appears to have been selected for pivotal development — the ORR was 72.4%, the DCR was 89.7%, and the median PFS was 14.1 months (95% CI: 8.3, not calculable) after a median follow-up of 13.6 months.

Safety data from the broader Phase 1/2 population of 368 patients showed no dose-limiting toxicities up to 18 mg/kg. At the 9 mg/kg dose, grade 3 or higher treatment-related adverse events occurred in 21.0% of patients. The rate of adverse events leading to dose reduction was 1.2%, and discontinuation due to treatment-related toxicity was also 1.2%. No treatment-related deaths were reported. The incidence of interstitial lung disease was 1.2%, all grade 1 — a figure that Innovent and the study's principal investigator, Binghe Xu, emphasized as a potential differentiator. "This 'high-efficacy, low-toxicity' therapeutic window may allow a broader range of patients to achieve sustained, high-quality treatment outcomes," Xu stated.

Zhou Hui, Innovent's Chief R&D Officer for Oncology, said the company will continue advancing what it describes as next-generation IO+ADC combinations and plans to explore IBI354 across multiple solid tumor indications. A second pivotal Phase III trial, HeriCare-Ovarian01, evaluating IBI354 in platinum-resistant ovarian cancer, is already underway. No specific timeline for regulatory submissions was disclosed.

Research context: IBI354 mechanism, HER2-positive breast cancer treatment landscape, and competitive positioning

IBI354 was developed using Innovent's proprietary SoloTx ADC platform. The molecule conjugates a HER2-directed monoclonal antibody to a camptothecin-derivative topoisomerase I inhibitor via a hydrophilic linker, achieving a drug-to-antibody ratio of 8. The high DAR is intended to maximize cytotoxic payload delivery to HER2-expressing tumor cells, while the hydrophobic payload is designed to produce a bystander effect against adjacent antigen-low or antigen-negative cells. Innovent has stated that IBI354 exhibits low systemic exposure of free toxin, which may contribute to its tolerability profile.

HER2 overexpression or amplification occurs in approximately 20% of breast cancers and is associated with aggressive disease biology and poor prognosis. The current first-line standard — trastuzumab, pertuzumab, and a taxane — was established by the CLEOPATRA trial, which demonstrated a median PFS of 18.7 months and a median overall survival of 56.5 months. No HER2-targeted ADC has yet been approved for first-line use in advanced HER2-positive breast cancer in China, though the global landscape is shifting rapidly. IBI354 does not appear to have received any US FDA designations such as Fast Track, Orphan Drug, or Breakthrough Therapy, and it remains unapproved in all jurisdictions.

The competitive field for HER2 ADC first-line breast cancer development is dense. Key competitors include:

• Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan (T-DXd; Enhertu), a HER2-targeted ADC with a topoisomerase I inhibitor payload that reported results from the Phase III DESTINY-Breast09 trial at ASCO 2025. T-DXd with or without pertuzumab achieved a median PFS of approximately 33 months versus 24.8 months for THP, with a hazard ratio of 0.60. The ILD rate was approximately 15% (any grade), with 2–3% at grade 3 or higher — substantially higher than IBI354's reported 1.2%.

• Jiangsu Hengrui Pharmaceuticals' SHR-A1811, another HER2-targeted ADC with a camptothecin-derivative payload (DAR ~5.7), which is in a Phase III first-line trial with a design closely analogous to both DESTINY-Breast09 and HeriCare-Breast01. Phase 1/2 data presented at ASCO 2024 showed an ORR of approximately 72% and a median PFS of approximately 14.8 months in later-line HER2-positive breast cancer, with an ILD rate of around 6%.

• BL-M07D1, developed by Sichuan Baili Pharmaceutical with ex-China rights licensed to Bristol Myers Squibb, a HER2-targeted ADC carrying a topoisomerase I inhibitor payload (Ed-04) at a DAR of 8. Phase 1/2 data presented at ASCO 2024 showed an ORR of approximately 75% in second-line-plus HER2-positive breast cancer, with a low ILD rate of approximately 3%. A Phase III trial has been initiated.

• RemeGen's disitamab vedotin (RC48; Aidixi), a HER2-targeted ADC with an MMAE payload approved in China for gastric and urothelial cancers, with Phase III breast cancer studies ongoing. Its differentiated payload class (auristatin rather than camptothecin) gives it a distinct toxicity profile.

• Jazz Pharmaceuticals' zanidatamab, a bispecific HER2-targeted antibody binding two non-overlapping epitopes, in Phase II/III development for HER2-positive breast cancer in combination with chemotherapy.

The central challenge for Innovent Biologics IBI354 is one of timing and differentiation. The DESTINY-Breast09 data have already established a new efficacy benchmark in the first-line HER2-positive breast cancer treatment setting, and regulatory submissions for T-DXd in this indication are anticipated. IBI354's Phase 1/2 efficacy data — a 72.4% ORR and 14.1-month median PFS — were generated in a heavily pretreated population and are not directly comparable to first-line results, making it premature to draw cross-trial conclusions. The safety profile, particularly the 1.2% ILD rate (all grade 1), is the most concrete point of differentiation. Whether that margin holds in a larger, less selected population, and whether it translates into a clinically meaningful advantage in treatment duration and quality of life, will determine IBI354's place in a field where multiple camptothecin-based HER2 ADCs are converging on the same indication simultaneously.

---

Spot something wrong? Report an issue with this article